222 related articles for article (PubMed ID: 7903306)
1. Characterization of human type I and type II IMP dehydrogenases.
Carr SF; Papp E; Wu JC; Natsumeda Y
J Biol Chem; 1993 Dec; 268(36):27286-90. PubMed ID: 7903306
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of human Molt-4 leukemia type II inosine 5'-monophosphate dehydrogenase by the 1,5-diazabicyclo[3.1.0]hexane-2,4-diones.
Barnes BJ; Eakin AE; Izydore RA; Hall IH
Biochemistry; 2000 Nov; 39(45):13641-50. PubMed ID: 11076502
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding.
Hager PW; Collart FR; Huberman E; Mitchell BS
Biochem Pharmacol; 1995 May; 49(9):1323-9. PubMed ID: 7763314
[TBL] [Abstract][Full Text] [Related]
4. Expression of human IMP dehydrogenase types I and II in Escherichia coli and distribution in human normal lymphocytes and leukemic cell lines.
Konno Y; Natsumeda Y; Nagai M; Yamaji Y; Ohno S; Suzuki K; Weber G
J Biol Chem; 1991 Jan; 266(1):506-9. PubMed ID: 1670768
[TBL] [Abstract][Full Text] [Related]
5. Purification, characterization, and kinetic analysis of inosine 5'-monophosphate dehydrogenase of Tritrichomonas foetus.
Verham R; Meek TD; Hedstrom L; Wang CC
Mol Biochem Parasitol; 1987 May; 24(1):1-12. PubMed ID: 2886911
[TBL] [Abstract][Full Text] [Related]
6. Monovalent cation activation and kinetic mechanism of inosine 5'-monophosphate dehydrogenase.
Xiang B; Taylor JC; Markham GD
J Biol Chem; 1996 Jan; 271(3):1435-40. PubMed ID: 8576135
[TBL] [Abstract][Full Text] [Related]
7. Identification of the IMP binding site in the IMP dehydrogenase from Tritrichomonas foetus.
Huete-Pérez JA; Wu JC; Whitby FG; Wang CC
Biochemistry; 1995 Oct; 34(42):13889-94. PubMed ID: 7577983
[TBL] [Abstract][Full Text] [Related]
8. Increased activity, amount, and altered kinetic properties of IMP dehydrogenase from mycophenolic acid-resistant neuroblastoma cells.
Hodges SD; Fung E; McKay DJ; Renaux BS; Snyder FF
J Biol Chem; 1989 Oct; 264(30):18137-41. PubMed ID: 2572589
[TBL] [Abstract][Full Text] [Related]
9. Human type I and II IMP dehydrogenases as drug targets.
Natsumeda Y; Carr SF
Ann N Y Acad Sci; 1993 Nov; 696():88-93. PubMed ID: 7906497
[No Abstract] [Full Text] [Related]
10. Characterization of the novel Trypanosoma brucei inosine 5'-monophosphate dehydrogenase.
Bessho T; Morii S; Kusumoto T; Shinohara T; Noda M; Uchiyama S; Shuto S; Nishimura S; Djikeng A; Duszenko M; Martin SK; Inui T; Kubata KB
Parasitology; 2013 May; 140(6):735-45. PubMed ID: 23369253
[TBL] [Abstract][Full Text] [Related]
11. Action of the active metabolites of tiazofurin and ribavirin on purified IMP dehydrogenase.
Yamada Y; Natsumeda Y; Weber G
Biochemistry; 1988 Mar; 27(6):2193-6. PubMed ID: 2897864
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of IMPDH by mycophenolic acid: dissection of forward and reverse pathways using capillary electrophoresis.
Fleming MA; Chambers SP; Connelly PR; Nimmesgern E; Fox T; Bruzzese FJ; Hoe ST; Fulghum JR; Livingston DJ; Stuver CM; Sintchak MD; Wilson KP; Thomson JA
Biochemistry; 1996 Jun; 35(22):6990-7. PubMed ID: 8679523
[TBL] [Abstract][Full Text] [Related]
13. Isolation and characterization of mycophenolic acid-resistant mutants of inosine-5'-monophosphate dehydrogenase.
Farazi T; Leichman J; Harris T; Cahoon M; Hedstrom L
J Biol Chem; 1997 Jan; 272(2):961-5. PubMed ID: 8995388
[TBL] [Abstract][Full Text] [Related]
14. Kinetic mechanism of human inosine 5'-monophosphate dehydrogenase type II: random addition of substrates and ordered release of products.
Wang W; Hedstrom L
Biochemistry; 1997 Jul; 36(28):8479-83. PubMed ID: 9214292
[TBL] [Abstract][Full Text] [Related]
15. Acid-base catalysis in the chemical mechanism of inosine monophosphate dehydrogenase.
Markham GD; Bock CL; Schalk-Hihi C
Biochemistry; 1999 Apr; 38(14):4433-40. PubMed ID: 10194364
[TBL] [Abstract][Full Text] [Related]
16. Human IMP dehydrogenase catalyzes the dehalogenation of 2-fluoro- and 2-chloroinosine 5'-monophosphate in the absence of NAD.
Antonino LC; Wu JC
Biochemistry; 1994 Feb; 33(7):1753-9. PubMed ID: 7906542
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design.
Colby TD; Vanderveen K; Strickler MD; Markham GD; Goldstein BM
Proc Natl Acad Sci U S A; 1999 Mar; 96(7):3531-6. PubMed ID: 10097070
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of inosine 5'-monophosphate dehydrogenase by the antiviral agent 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide 5'-monophosphate.
Wang W; Papov VV; Minakawa N; Matsuda A; Biemann K; Hedstrom L
Biochemistry; 1996 Jan; 35(1):95-101. PubMed ID: 8555204
[TBL] [Abstract][Full Text] [Related]
19. Cloning, characterization and validation of inosine 5'-monophosphate dehydrogenase of Babesia gibsoni as molecular drug target.
Cao S; Aboge GO; Terkawi MA; Zhou M; Luo Y; Yu L; Li Y; Goo Y; Kamyingkird K; Masatani T; Suzuki H; Igarashi I; Nishikawa Y; Xuan X
Parasitol Int; 2013 Apr; 62(2):87-94. PubMed ID: 23142571
[TBL] [Abstract][Full Text] [Related]
20. IMP dehydrogenase from the intracellular parasitic protozoan Eimeria tenella and its inhibition by mycophenolic acid.
Hupe DJ; Azzolina BA; Behrens ND
J Biol Chem; 1986 Jun; 261(18):8363-9. PubMed ID: 2873141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
